Replimune shares plummet as skin cancer therapy fails mid-stage study
Replimune Group's experimental combination therapy for skin cancer, involving its lead therapy RP1 and Regeneron's Libtayo, failed to significantly remove cancerous lesions in a mid-stage study. However, the company stated that the rate of complete disappearance of tumors was just short of statistical significance. The study focused on improvements in complete response rate (CRR) and overall response rate (ORR). Replimune will continue the trial as planned under its agreement with Regeneron.
Disclaimer : Mytimesnow (MTN) lets you explore worldwide viral news just by analyzing social media trends. Tap read more at source for full news. The inclusion of any links does not necessarily imply any endorsement of the views expressed within them.
